Despite low obesity rate, Mass. has the third-highest increase in weight-loss drug prescriptions nationwide. Why?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.
Sweeping review suggests effect of weight-loss drugs on 175 conditions
A study by the Department of Veterans Affairs on the relationship between GLP-1 weight-loss drugs and 175 diseases and conditions supports a lot of what scientists already suspected about potential benefits,
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.
Popular weight-loss drugs linked to new health risks and benefits
Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as Ozempic and Wegovy.
Weight-loss drugs reduce risk of Alzheimer’s, large study shows
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial
Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
CNET on MSN1h
Want Precise Weight Measurements? Here's When to Step on the Scale
Store and use your weight scale on a solid, flat surface. Stand barefoot on your scale, keeping your weight distributed ...
Does The Sauna Burn Calories? Experts Reveal How It Impacts Weight Loss
Even if we work off the study premise that sitting in a sauna for 10 minutes burns, on average, 73 calories, that equates to ...
6 Ways to Lose Weight Without Exercising This Year
There are plenty of tips on how to lose weight fast without exercise, from sketchy pills to crash diets that do more harm ...
Experts with Mercy discuss differences between bariatric surgery and drugs for weight loss
When it comes to medically assisted weight loss, there’s two main schools of thought: either weight loss drugs, like the ...
Costco Employee Reveals the 16 Best Weight Loss Foods to Buy Right Now
A Costco employee reveals the 16 best foods for weight loss, from high-protein snacks to healthy meal essentials.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
TheHealthSite on MSN1d
Amla Vs Orange: Which One Is Better For Weight Loss?
Are you on your weight loss journey and looking for the best superfood that can support you? Scroll down to know whether you ...